Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Primary Purpose
Exercise Triggered Asthma, Gastroesophageal Reflux
Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Nexium
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Exercise Triggered Asthma focused on measuring asthma, GERD, reflux, exercise
Eligibility Criteria
Inclusion Criteria:
We plan to take athletes (cyclists) with GER (heartburn symptoms on a daily-weekly basis which are either improved by a trial of acid suppression or objectively documented via pH/endoscopic testing- this may include during exercise) who experience one or more of the following symptoms during exercise, limiting their perceived ability to exercise to full capacity:
- choking
- cough
- wheezing
- shortness of breath
- chest tightness during exercise
- Athletes will be defined as persons who exercise on a routine basis (at least 3 times a week on average) for at least the past 6 months.
- Subjects must be at least 18 years old.
Exclusion Criteria:
- Pregnancy
- Age less than 18 years or greater than 65 years
- Abnormal methacholine challenge tests will not exclude one from enrollment as (has been documented in a prior study) often patients with GER will have heightened bronchial reactivity.
Sites / Locations
- University of Utah Health Sciences Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
To assess whether acid suppression results in improvement in respiratory parameters in symptomatic patients.
Secondary Outcome Measures
To assess whether acid reflux events increase during exercise in athletes with symptomatic heartburn or respiratory discomfort during exertion.
To assess whether long term acid suppression results in enhanced athletic performance
Full Information
NCT ID
NCT00444236
First Posted
March 6, 2007
Last Updated
January 19, 2016
Sponsor
University of Utah
Collaborators
AstraZeneca
1. Study Identification
Unique Protocol Identification Number
NCT00444236
Brief Title
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Official Title
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Terminated
Why Stopped
The sponsor decided to terminate the study due to slow enrollment.
Study Start Date
April 2007 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah
Collaborators
AstraZeneca
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
We propose that acid reflux affects respiratory dynamics (breathing) in patients who are exercising and that athletes improve their exercise capacity with acid suppression therapy. It is our intent to determine whether treatment of GER with strong acid suppression may alleviate symptoms, improve exercise capacity, and improve quality of life.
Detailed Description
This is a randomized, blinded, cross-over trial. We plan to take athletes with classical GER, cough, shortness of breath, chest tightness during exercise and subject them to complete pulmonary function testing in conjunction with exercise and pH testing. We will assess whether such athletes experience an increase in reflux duration and episodes during exercise. The athletes will be randomized (in a cross over fashion) to acid suppression (BID Nexium 40 mg) or placebo for 10-12 weeks. Both the athletes and investigators will be blinded. After 10-12 weeks, exercise testing (ramp protocol with VO2 and anaerobic threshold) with concurrent respiratory function testing will be repeated along with symptom assessment. After a brief washout period of 1-2 weeks, the athletes will then cross-over to the other study medication for 10-12 weeks. Again, at the end of the study period, symptomatic relief as well as respiratory function improvement will be assessed by repeating the initial exercise regimen. The exercise regimens during these medication regimens will not be held stable as indirectly, as a results of "feeling better or worse" from the medication/placebo, these patients may increase/ decrease their exercise routine, resulting in changes in their overall endurance, anaerobic threshold, etc (our endpoints). By keeping the regimen stable, we do not allow for the changes to occur which are large enough to detect.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Exercise Triggered Asthma, Gastroesophageal Reflux
Keywords
asthma, GERD, reflux, exercise
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Nexium
Other Intervention Name(s)
esomeprazole
Intervention Description
nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
matching placebo for active drug
Primary Outcome Measure Information:
Title
To assess whether acid suppression results in improvement in respiratory parameters in symptomatic patients.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To assess whether acid reflux events increase during exercise in athletes with symptomatic heartburn or respiratory discomfort during exertion.
Time Frame
6 months
Title
To assess whether long term acid suppression results in enhanced athletic performance
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
We plan to take athletes (cyclists) with GER (heartburn symptoms on a daily-weekly basis which are either improved by a trial of acid suppression or objectively documented via pH/endoscopic testing- this may include during exercise) who experience one or more of the following symptoms during exercise, limiting their perceived ability to exercise to full capacity:
choking
cough
wheezing
shortness of breath
chest tightness during exercise
Athletes will be defined as persons who exercise on a routine basis (at least 3 times a week on average) for at least the past 6 months.
Subjects must be at least 18 years old.
Exclusion Criteria:
Pregnancy
Age less than 18 years or greater than 65 years
Abnormal methacholine challenge tests will not exclude one from enrollment as (has been documented in a prior study) often patients with GER will have heightened bronchial reactivity.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathryn A Peterson, MD, MSci
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Utah Health Sciences Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
We'll reach out to this number within 24 hrs